SERA
Sera Prognostics, Inc. Class A Common Stock
stockNASDAQ
sera prognostics is a private biotechnology company developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications. sera's tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. the company has assembled a strong management team and board of directors with significant clinical development and women's healthcare diagnostic experience. the company is supported by a strong group of investors, including the bill & melinda gates foundation, chione, ltd, domain associates, interwest partners, catalyst health ventures, upstart life sciences capital, and osage university partners. the company is working with the bill & melinda gates foundation to translate its discoveries and develop technologies to benefit women and infants in underserved countries worldwide. sera prognostics is located in salt lake city, utah. sera launched its first diagnos
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.02 | 2026-09-28 | +2.48% | 0.327 |
| 1M | 2.02 | 2026-09-04 | +2.48% | 0.689 |
| 3M | 2.09 | 2026-07-06 | -0.96% | 0.087 |
| 6M | 2.30 | 2026-04-06 | -10.00% | 0.134 |
| 1Y | 3.26 | 2025-10-06 | -36.50% | 0.907 |
| 2Y | 7.21 | 2024-10-04 | -71.29% | — |
| 5Y | 11.01 | 2021-10-05 | -81.20% | 0.528 |
Sera Prognostics, Inc. Class A Common Stock (NASDAQ:SERA) stock price today is $2.07, and today's volume is 21,876. SERA is up 1.471% today. The 30 day average volume is 21,600. SERA market cap is $81.66M with 39.45M shares outstanding.